Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial

Bitget2026/11/04 14:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Karyopharm Therapeutics will present selinexor myelofibrosis trial data at the American Society of Hematology meeting on Dec. 12-13, 2026.
Phase 3 SENTRY findings show ongoing clinical benefit through week 48 with selinexor combined with ruxolitinib; presentation is scheduled for Dec. 13.
Early Phase 2 SENTRY-2 results support selinexor monotherapy activity in JAK inhibitor-naïve myelofibrosis; findings will be presented Dec. 12.
A Dec. 12 poster will feature updated Phase 1b/2 STOMP results evaluating selinexor with mezigdomide and dexamethasone in relapsed/refractory multiple myeloma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040901PR_NEWS_USPR_____NE88503) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial

You may also like

Crypto prices